MDXG
MiMedx Group, Inc.
Biotechnology
Market Cap$548M
5Y Perf.+2.8%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
MDXG vs TELA vs XTNT vs ATRC
Revenue, margins, valuation, and 5-year total return — side by side.
TELA
TELA Bio, Inc.
Medical - Devices
Market Cap$44M
5Y Perf.-92.0%
XTNT
Xtant Medical Holdings, Inc.
Medical - Devices
Market Cap$80M
5Y Perf.-53.7%
ATRC
AtriCure, Inc.
Medical - Instruments & Supplies
Market Cap$1.41B
5Y Perf.-41.9%
MDXG vs TELA vs XTNT vs ATRC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MDXG | TELA | XTNT | ATRC |
|---|---|---|---|---|
| Industry | Biotechnology | Medical - Devices | Medical - Devices | Medical - Instruments & Supplies |
| Market Cap | $548M | $44M | $80M | $1.41B |
| Revenue (TTM) | $389M | $77M | $133M | $552M |
| Net Income (TTM) | $31M | $-39M | $2M | $-5M |
| Gross Margin | 81.0% | 67.2% | 62.0% | 75.5% |
| Operating Margin | 10.2% | -46.0% | 4.8% | -0.4% |
| Forward P/E | 295.2x | — | — | 370.7x |
| Total Debt | $23M | $43M | $35M | $88M |
| Cash & Equiv. | $166M | $53M | $6M | $167M |
MDXG vs TELA vs XTNT vs ATRC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MDXG
TELA
XTNT
ATRC
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| MiMedx Group, Inc. (MDXG) | 100 | 102.8 | +2.8% |
| TELA Bio, Inc. (TELA) | 100 | 8.0 | -92.0% |
| Xtant Medical Holdi… (XTNT) | 100 | 46.3 | -53.7% |
| AtriCure, Inc. (ATRC) | 100 | 58.1 | -41.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MDXG vs TELA vs XTNT vs ATRC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MDXG leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. TELA Bio, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. XTNT also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
MDXG
MiMedx Group, Inc.
The Value Play
MDXG carries the broadest edge in this set and is the clearest fit for value and quality.
- Lower P/E (295.2x vs 370.7x)
- 7.9% margin vs TELA's -50.6%
- 9.7% ROA vs TELA's -53.1%, ROIC 42.3% vs -151.6%
Best for: value and quality
TELA
TELA Bio, Inc.
The Income Pick
TELA is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- beta 0.57
- Lower volatility, beta 0.57, current ratio 5.01x
- Beta 0.57, current ratio 5.01x
- Beta 0.57 vs MDXG's 1.22
Best for: income & stability and sleep-well-at-night
XTNT
Xtant Medical Holdings, Inc.
The Growth Play
XTNT is the clearest fit if your priority is growth exposure.
- Rev growth 28.4%, EPS growth 107.7%, 3Y rev CAGR 28.5%
- 28.4% revenue growth vs ATRC's 14.9%
Best for: growth exposure
ATRC
AtriCure, Inc.
The Long-Run Compounder
ATRC is the clearest fit if your priority is long-term compounding.
- 95.1% 10Y total return vs MDXG's -48.5%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | XTNT | 28.4% revenue growth vs ATRC's 14.9% |
| Value | MDXG | Lower P/E (295.2x vs 370.7x) |
| Quality / Margins | MDXG | 7.9% margin vs TELA's -50.6% |
| Stability / Safety | TELA | Beta 0.57 vs MDXG's 1.22 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | TELA | +15.8% vs MDXG's -47.1% |
| Efficiency (ROA) | MDXG | 9.7% ROA vs TELA's -53.1%, ROIC 42.3% vs -151.6% |
MDXG vs TELA vs XTNT vs ATRC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
FY 2024
FY 2025
MDXG vs TELA vs XTNT vs ATRC — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMDXGLAGGINGATRC
Who Leads Where
MDXG leads in 3 of 6 categories
TELA leads 0 • XTNT leads 0 • ATRC leads 0 • 2 tied
Explore the data ↓ATRCAtriCure, Inc.
0leads
XTNTXtant Medical Holding…
0leads
TELATELA Bio, Inc.
0leads
MDXGMiMedx Group, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs TELAvs XTNTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
MDXG4/6
Valuation MetricsMultiples, price ratios, and targets
MDXG3/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MDXG9/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
MDXG leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ATRC is the larger business by revenue, generating $552M annually — 7.2x TELA's $77M. MDXG is the more profitable business, keeping 7.9% of every revenue dollar as net income compared to TELA's -50.6%. On growth, XTNT holds the edge at +19.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | MDXGMiMedx Group, Inc. | TELATELA Bio, Inc. | XTNTXtant Medical Hol… | ATRCAtriCure, Inc. |
|---|---|---|---|---|
| RevenueTrailing 12 months | $389M | $77M | $133M | $552M |
| EBITDAEarnings before interest/tax | $53M | -$34M | $11M | $13M |
| Net IncomeAfter-tax profit | $31M | -$39M | $2M | -$5M |
| Free Cash FlowCash after capex | $66M | -$32M | $5M | $54M |
| Gross MarginGross profit ÷ Revenue | +81.0% | +67.2% | +62.0% | +75.5% |
| Operating MarginEBIT ÷ Revenue | +10.2% | -46.0% | +4.8% | -0.4% |
| Net MarginNet income ÷ Revenue | +7.9% | -50.6% | +1.3% | -0.8% |
| FCF MarginFCF ÷ Revenue | +17.0% | -40.9% | +3.9% | +9.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | -33.1% | +9.1% | +19.0% | +14.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.4% | +54.8% | +123.7% | +101.6% |
MDXG leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
MDXG leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, MDXG's 5.1x EV/EBITDA is more attractive than ATRC's 77.7x.
| Metric | MDXGMiMedx Group, Inc. | TELATELA Bio, Inc. | XTNTXtant Medical Hol… | ATRCAtriCure, Inc. |
|---|---|---|---|---|
| Market CapShares × price | $548M | $44M | $80M | $1.4B |
| Enterprise ValueMkt cap + debt − cash | $405M | $35M | $109M | $1.3B |
| Trailing P/EPrice ÷ TTM EPS | 11.53x | -0.83x | -4.75x | -115.83x |
| Forward P/EPrice ÷ next-FY EPS est. | 295.20x | — | — | 370.67x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 5.14x | — | — | 77.75x |
| Price / SalesMarket cap ÷ Revenue | 1.31x | 0.64x | 0.68x | 2.63x |
| Price / BookPrice ÷ Book value/share | 2.15x | 1.10x | 1.77x | 2.70x |
| Price / FCFMarket cap ÷ FCF | 7.51x | — | — | 29.15x |
MDXG leads this category, winning 3 of 6 comparable metrics.
Profitability & Efficiency
MDXG leads this category, winning 9 of 9 comparable metrics.
Profitability & Efficiency
MDXG delivers a 12.9% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-3 for TELA. MDXG carries lower financial leverage with a 0.09x debt-to-equity ratio, signaling a more conservative balance sheet compared to TELA's 1.51x. On the Piotroski fundamental quality scale (0–9), MDXG scores 5/9 vs XTNT's 2/9, reflecting solid financial health.
| Metric | MDXGMiMedx Group, Inc. | TELATELA Bio, Inc. | XTNTXtant Medical Hol… | ATRCAtriCure, Inc. |
|---|---|---|---|---|
| ROE (TTM)Return on equity | +12.9% | -2.7% | +3.8% | -1.0% |
| ROA (TTM)Return on assets | +9.7% | -53.1% | +1.8% | -0.7% |
| ROICReturn on invested capital | +42.3% | -151.6% | -12.8% | -0.6% |
| ROCEReturn on capital employed | +25.7% | -51.4% | -17.9% | -0.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 | 2 | 5 |
| Debt / EquityFinancial leverage | 0.09x | 1.51x | 0.82x | 0.18x |
| Net DebtTotal debt minus cash | -$144M | -$10M | $29M | -$79M |
| Cash & Equiv.Liquid assets | $166M | $53M | $6M | $167M |
| Total DebtShort + long-term debt | $23M | $43M | $35M | $88M |
| Interest CoverageEBIT ÷ Interest expense | 25.32x | -6.99x | 1.55x | 0.47x |
MDXG leads this category, winning 9 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — TELA and XTNT each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MDXG five years ago would be worth $3,712 today (with dividends reinvested), compared to $853 for TELA. Over the past 12 months, TELA leads with a +15.8% total return vs MDXG's -47.1%. The 3-year compound annual growth rate (CAGR) favors XTNT at -4.3% vs TELA's -51.9% — a key indicator of consistent wealth creation.
| Metric | MDXGMiMedx Group, Inc. | TELATELA Bio, Inc. | XTNTXtant Medical Hol… | ATRCAtriCure, Inc. |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -43.1% | -3.5% | -24.0% | -29.2% |
| 1-Year ReturnPast 12 months | -47.1% | +15.8% | +10.0% | -8.3% |
| 3-Year ReturnCumulative with dividends | -36.6% | -88.9% | -12.3% | -41.8% |
| 5-Year ReturnCumulative with dividends | -62.9% | -91.5% | -66.1% | -64.2% |
| 10-Year ReturnCumulative with dividends | -48.5% | -91.8% | -97.8% | +95.1% |
| CAGR (3Y)Annualised 3-year return | -14.1% | -51.9% | -4.3% | -16.5% |
Evenly matched — TELA and XTNT each lead in 2 of 6 comparable metrics.
Risk & Volatility
Evenly matched — TELA and ATRC each lead in 1 of 2 comparable metrics.
Risk & Volatility
TELA is the less volatile stock with a 0.57 beta — it tends to amplify market swings less than MDXG's 1.22 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ATRC currently trades 64.4% from its 52-week high vs MDXG's 46.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MDXGMiMedx Group, Inc. | TELATELA Bio, Inc. | XTNTXtant Medical Hol… | ATRCAtriCure, Inc. |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.22x | 0.57x | 0.69x | 1.03x |
| 52-Week HighHighest price in past year | $7.99 | $2.20 | $0.95 | $43.18 |
| 52-Week LowLowest price in past year | $3.02 | $0.50 | $0.44 | $26.62 |
| % of 52W HighCurrent price vs 52-week peak | +46.2% | +50.0% | +60.0% | +64.4% |
| RSI (14)Momentum oscillator 0–100 | 49.3 | 62.7 | 60.9 | 45.0 |
| Avg Volume (50D)Average daily shares traded | 1.4M | 188K | 142K | 669K |
Evenly matched — TELA and ATRC each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: MDXG as "Buy", ATRC as "Buy". Consensus price targets imply 171.0% upside for MDXG (target: $10) vs 82.3% for ATRC (target: $51).
| Metric | MDXGMiMedx Group, Inc. | TELATELA Bio, Inc. | XTNTXtant Medical Hol… | ATRCAtriCure, Inc. |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | — | Buy |
| Price TargetConsensus 12-month target | $10.00 | — | — | $50.67 |
| # AnalystsCovering analysts | 15 | — | — | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.6% | 0.0% | 0.0% | +0.8% |
Insufficient data to determine a leader in this category.
Key Takeaway
MDXG leads in 3 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 2 categories are tied.
Best OverallMiMedx Group, Inc. (MDXG)Leads 3 of 6 categories
Loading custom metrics...
MDXG vs TELA vs XTNT vs ATRC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is MDXG or TELA or XTNT or ATRC a better buy right now?
For growth investors, Xtant Medical Holdings, Inc.
(XTNT) is the stronger pick with 28. 4% revenue growth year-over-year, versus 14. 9% for AtriCure, Inc. (ATRC). MiMedx Group, Inc. (MDXG) offers the better valuation at 11. 5x trailing P/E (295. 2x forward), making it the more compelling value choice. Analysts rate MiMedx Group, Inc. (MDXG) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MDXG or TELA or XTNT or ATRC?
On forward P/E, MiMedx Group, Inc.
is actually cheaper at 295. 2x.
03Which is the better long-term investment — MDXG or TELA or XTNT or ATRC?
Over the past 5 years, MiMedx Group, Inc.
(MDXG) delivered a total return of -62. 9%, compared to -91. 5% for TELA Bio, Inc. (TELA). Over 10 years, the gap is even starker: ATRC returned +95. 1% versus XTNT's -97. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MDXG or TELA or XTNT or ATRC?
By beta (market sensitivity over 5 years), TELA Bio, Inc.
(TELA) is the lower-risk stock at 0. 57β versus MiMedx Group, Inc. 's 1. 22β — meaning MDXG is approximately 114% more volatile than TELA relative to the S&P 500. On balance sheet safety, MiMedx Group, Inc. (MDXG) carries a lower debt/equity ratio of 9% versus 151% for TELA Bio, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — MDXG or TELA or XTNT or ATRC?
By revenue growth (latest reported year), Xtant Medical Holdings, Inc.
(XTNT) is pulling ahead at 28. 4% versus 14. 9% for AtriCure, Inc. (ATRC). On earnings-per-share growth, the picture is similar: AtriCure, Inc. grew EPS 74. 7% year-over-year, compared to 14. 3% for MiMedx Group, Inc.. Over a 3-year CAGR, TELA leads at 33. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MDXG or TELA or XTNT or ATRC?
MiMedx Group, Inc.
(MDXG) is the more profitable company, earning 11. 6% net margin versus -54. 6% for TELA Bio, Inc. — meaning it keeps 11. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MDXG leads at 15. 3% versus -49. 2% for TELA. At the gross margin level — before operating expenses — MDXG leads at 82. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MDXG or TELA or XTNT or ATRC more undervalued right now?
On forward earnings alone, MiMedx Group, Inc.
(MDXG) trades at 295. 2x forward P/E versus 370. 7x for AtriCure, Inc. — 75. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MDXG: 171. 0% to $10. 00.
08Which pays a better dividend — MDXG or TELA or XTNT or ATRC?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is MDXG or TELA or XTNT or ATRC better for a retirement portfolio?
For long-horizon retirement investors, TELA Bio, Inc.
(TELA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 57)). Both have compounded well over 10 years (TELA: -91. 8%, MDXG: -48. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MDXG and TELA and XTNT and ATRC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MDXG is a small-cap high-growth stock; TELA is a small-cap high-growth stock; XTNT is a small-cap high-growth stock; ATRC is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(MDXG: -33.1% · TELA: 9.1%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.